Cognitive-Behavioral Couple Therapy Provided Pain Relief from Vulvar Pain

PainRelief.com Interview with:
Sophie Bergeron, Ph.D.
Canada Research Chair in Intimate Relationships and Sexual Wellbeing
Past-President, Society for Sex Therapy and Research
Professeure titulaire/Professor
Département de psychologie 
Université de Montréal 

Dr. Bergeron

PainRelief.com:  What is the background for this study?

Response: Chronic pain problems involving the female reproductive system are major health concerns in women of all ages. As conditions which are poorly understood and often misdiagnosed or ignored, they entail a great personal cost to patients and a significant financial cost to society.

One such condition is vulvodynia, or chronic unexplained vulvar pain. Up to 8% of women under 40 may experience idiopathic vulvar pain during their lifetimes. Provoked vestibulodynia (PVD) – an acute recurrent pain localized within the vulvar vestibule and experienced primarily during sexual intercourse – is suspected to be the most frequent cause of vulvodynia in premenopausal women.

Despite its high prevalence and negative impact on psychosexual functioning of both affected women and their partners, there has been a paucity of controlled research to provide empirically validated treatments for afflicted couples. This randomized clinical trial compared a novel cognitive-behavioral couple therapy (CBCT) and topical lidocaine for PVD.

Routine Lumbar X-Rays of Limited Value in Assessing Low Back Pain

PainRelief.com Interview with:
Lingxiao Chen
 | MBBS, MMed, PhD Candidate
The University of Sydney
Institute of Bone and Joint Research | The Kolling Institute
Sydney Medical School | Faculty of Medicine and Health
Statistical Editor of BMJ Open Sport & Exercise Medicine

back pain

PainRelief.com: What is the background for this study?

Response: Current guidelines for treatment of low back pain (LBP) do not recommend routinely using diagnostic imaging, except when patients either present with severe, progressive neurologic deficits or with signs or symptoms indicative of a serious or specific underlying condition (eg, fracture or cancer). Nonetheless, diagnostic imaging is still widely used in clinical practice for low back pain. Previous studies, using mostly cross-sectional data, provide conflicting evidence of an association between lumbar spine radiographic changes and the severity of back pain–related disability. Such conflicting evidence may be associated with widely unnecessary diagnostic imaging of the lumbar spine.

Continue reading

Diabetic Neuropathy: High-Frequency Spinal Cord Stimulation Offers Pain Relief

PainRelief.com Interview with:
Erika A. Petersen, MD, FAANS, FACS
Professor of Neurosurgery
Residency Program Director
UAMS Department of Neurosurgery

PainRelief.com: What is the background for this study?

Response: Painful diabetic neuropathy is a common occurrence for patients with diabetes and can have a tremendous negative impact on their quality of life. Currently, the best available treatments include several types of medications and topical solutions, but there are many patients who do not achieve adequate pain relief or cannot tolerate side effects from these treatments. We need new options for patients who have tried the recommended first- and second-line treatments but still suffer with severe pain.

Continue reading

Targeted Smartphone Exercise Program Can Provide Pain Relief from Knee Arthritis

PainRelief.com Interview with:
Ana M Valdes MA PhD
Professor in Molecular and Genetic Epidemiology
NIHR Nottingham Biomedical Research Centre – Research Area Lead
Associate Editor European Journal of Clinical Nutrition
School of Medicine
University of Nottingham

Dr. Valdes

PainRelief.com:  What is the background for this study?

Response: Knee osteoarthritis and knee pain affect a large proportion of middle age and aging individuals and this are  an increasing problem. Physical exercises aimed at strengthening and stabilising the muscles in the legs and hips  are known to be highly effective in reducing pain and improving the ability to walk and get on with life. But a key challenge is how to deliver such gradual exercises in a way that does not require people to travel to see a physiotherapist or a doctor, particularly given the issues raised by  lockdown both in terms of the Covid-secure challenges face to face visits and also given the strain that the pandemic has put on health services.  

Our  study was the first randomised controlled trial in the UK where we were had people with painful knee osteoarthritis either do only what their doctors normally recommend or, in addition, follow a programme of exercised developed in Sweden delivered via  smartphone app. The research participants were assessed for knee inflammation, knee pain, pain sensitivity around the knee, muscle strength, and ability to walk and get up from a chair both before and after the 6 week smartphone delivered intervention (or a 6 week period simply following any advice they had from their family doctor).

Redheads May Experience Pain Differently

PainRelief.com Interview with:
David E. Fisher MD, PhD
Edward Wigglesworth Professor & Chairman
Dept of Dermatology
Director, Melanoma Program MGH Cancer Center
Director, Cutaneous Biology Research Center
Massachusetts General Hospital
Harvard Medical School

Dr. Fisher

PainRelief.com:  What is the background for this study?

Response: This study followed up on prior published work from other investigators which demonstrated altered pain thresholds in humans and mice who had the redhair light-skin phenotypes.  The key focus of our current study was to firstly validate the overall findings, and then to  the mechanistic basis for the differences.  Of note, our laboratory does not primarily focus on the science of pain or nociceptive, but rather on skin and melanoma. For this reason we had accumulated a number of valuable genetic models of pigmentation (such as redhaired mice harboring alterations in the identical gene implicated in human red hair).  These mouse models served as the key resources for carrying out the current study.

Continue reading

Migraine: Galcanezumab (Emgality®) for Pain Relief in Patients with Previous Preventive Medication Failures

PainRelief.com Interview with:
Dulanji K. Kuruppu, MD

Medical Advisor, Migraine & Headache Disorders
US Medical Affairs
Eli Lilly and Company
LTC-South, Indianapolis IN 46221 U.S.A.

PainRelief.com:  What is the background for this study?

Response: Galcanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine and for the treatment of episodic cluster headache in adults. The CONQUER study assessed the efficacy and safety of galcanezumab in 462 adults with episodic or chronic migraine who previously did not benefit from 2 to 4 standard-of-care migraine preventive medication categories. This study consisted of a 3-month double-blind, placebo-controlled period (months 1-3) followed by an open-label period (months 4-6). The primary endpoint, which was the mean change from baseline in the number of monthly migraine headache days for galcanezumab vs placebo over months 1-3, was met. In this post-hoc analysis, we assessed onset of effect of galcanezumab in the CONQUER population.

Continue reading

Auricular Acupuncture for Musculoskeletal Pain Relief in Cancer Patients

MedicalResearch.com Interview with:

Jun JMaoMD, MSCE
Integrative Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Jun J. Mao

MedicalResearch.com:  What is the background for this study?

Response: The opioid crisis has fueled growing interest in non-pharmacological pain management options. Last year, Medicare approved insurance coverage of acupuncture for chronic low back pain. Despite this progress, many cancer survivors continue to struggle with chronic pain. 

Continue reading

Radiofrequency Ablation Provides Faster Pain Relief for Patients with Bone Metastases

PainRelief.com Interview with:
Jason R. Levy, MD, FSIR
Vascular and Interventional Radiologist
Northside Hospital in Atlanta, Georgia

Dr. Levy

PainRelief.com:  What is the background for this study?

Response: For patients whose cancer has spread to their bones, their pain is often treated using radiation, which can take weeks to provide relief. In our study we examined the effectiveness of Radiofrequency Ablation (RFA) for the palliative treatment of patients with painful osseous metastases.

Radiofrequency Ablation is a minimally invasive treatment that uses radiofrequency waves to create heat that kills tumor cells and destroys nerve fibers to reduce transmission of pain signals to the brain. The procedure was followed up with cement injections to help stabilize the bone and prevent fractures that often occur following other treatments.

Continue reading

Aimovig® plus OnabotulinumtoxinA (onabot) For Migraine Pain Relief

PainRelief.com Interview with:
Fred Cohen, MD
Department of Medicine, 
Montefiore Medical Center and the Albert Einstein College of Medicine
Bronx, New York

Dr. Fred Cohen

PainRelief.com:  What is the background for this study?

Response: OnabotulinumtoxinA (onabot) and calcitonin gene-related peptide monoclonal antibodies (CGRP-targeted mAbs) are two medications used to treat chronic migraine. While both have been shown to significantly reduce monthly headache days, they are some patients that require further treatment after receiving one of these therapies. Prior to this study, there was limited data on the efficacy and safety of concomitant treatment with onabot and a CGRP-targeted mAb. 

Continue reading

Lower Ketamine Dose Can Provide Pain Relief for Acute Pain in ER

PainRelief.com Interview with:
Shannon Lovett, MD, FACEP
Associate Professor
Associate Medical Director, ED Clinical Operations
Department of Emergency Medicine
Stritch School of Medicine

Dr. Lovett

PainRelief.com:  What is the background for this study?  What types of pain were treated?

Response: The opioid crisis has led emergency medicine providers to utilize other medications to treat pain, including ketamine. Prior to our study, there was a range of recommended ketamine doses in the treatment of pain, and the most frequently studied dose demonstrating analgesic efficacy was 0.3 mg/kg. We challenged that dose by comparing a lower dose, 0.15 mg/kg, to 0.3 mg/kg of IV ketamine for acute moderate to severe pain in the emergency department. We treated acute (onset < 7 days) abdominal, back, flank, musculoskeletal, and headache pain. 

Continue reading